Celator's AML drug gets fast track; Piramal buys a CDMO in Kentucky;

@FierceBiotech: ICYMI: Exclusive: Constellation chops staff, plots go-it-alone strategy as Genentech option deadline looms. Report | Follow @FierceBiotech

@JohnCFierce: Alzheimer's investigators open a new front in BACE1 war. More from FierceBiotechResearch | Follow @JohnCFierce

@DamianFierce: A CF patient taking 's Kalydeco will be a guest of Michelle Obama at the State of the Union tonight. More | Follow @DamianFierce

> Ewing, NJ-based Celator Pharmaceuticals ($CPXX) says that the FDA granted fast-track designation for CPX-351 (cytarabine:daunorubicin) for the treatment of elderly patients with secondary acute myeloid leukemia. Release

> India's Piramal Enterprises said it was on the cusp of buying a CDMO founded at the University of Kentucky. Report

Medical Device News

@FierceMedDev: ICYMI: Researchers develop needle-free temporary tattoo for glucose monitoring. Article | Follow @FierceMedDev

@VarunSaxena2: Piramal buys Coldstream - The HinduMore | Follow @VarunSaxena2

@EmilyWFierce: Carmat notches a win as artificial heart patient returns home. More | Follow @EmilyWFierce

> FDA to avoid regulating most wearables, seeking to reduce medical device regulation overall. News

> India opens medical device industry to foreign direct investment. Report

Pharma News

@FiercePharma: MSF urges GSK, Pfizer to slash pneumococcal vaccine prices. Report from FierceVaccines | Follow @FiercePharma

@CarlyHFierce: ICYMI: Actavis working to add Allergan CEO Pyott to board: Reuters. Story | Follow @CarlyHFierce

> J&J's pharma unit 'fastest-growing' in the drug business, CEO Gorsky says. Report

> GlaxoSmithKline rejected e-cig buy to beef up stop-smoking franchise. Article

Biotech IT News

> Personalis raises $33M to scale up pharma-facing genomics operation. Report

> 10X Genomics exits stealth mode with $80M, plan to improve Illumina tech. News

> Novartis teams with Qualcomm on $100M digital health fund. Item

> Genentech teams with Venter's HLI as Roche group continues genomics push. Story

> 23andMe inks Pfizer deal, eyes 2015 resolution of FDA dispute. Article

CRO News

> Clinipace banks $50M to scout for more deals. Story

> Evotec strikes an R&D deal focused on addiction. More

> AMRI inks a 10-year NIH deal with $37M on the line. News

> Ergomed posts a big year with more in store for 2015. Article

> Sanofi taps Catalent for antibody R&D. Report

Animal Health News

> Annual sales of animal health products stable at $7.5B. Item

> China bans import of U.S. poultry products on avian flu fear. Report

> Microbiome dealmaking hits animal health with Metanome-Companion PBx linkup. More

> PetMed's sales fall but profit margins expand on rising demand for pricier products. Story

> Zoetis, IDEXX, Schein among animal health scene-stealers at JP Morgan confab. Article

Biotech Research News

> Genetic error highlights a new approach to Fragile X syndrome. Report

> Microbiome research opens a new pathway for autoimmune disease. Article

> Tracking tech illuminates T cells for immuno-oncology research. Item

> Michigan investigators finger ATDC gene for aggressive pancreatic cancer. Story

> Alzheimer's investigators open a new front in BACE1 war. More

Pharma Manufacturing News

> Actavis recalling 65,000 bottles of generic seizure drug. News

> FDA raises issues with another Apotex plant. Article

> India makes move to reduce reliance on Chinese APIs. Item

> Boehringer Ingelheim picks up contract work for Sanofi mAbs. News

> India's Piramal says it will snatch up university CDMO for its injectables skills. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.